Kelsey Stephen Michael 4

What Happened
Kelsey Stephen Michael, President, Research and Development at Revolution Medicines (RVMD), sold 4,302 shares on March 17, 2026 at $99.48 per share, generating proceeds of $427,965. The sale was reported on a Form 4 filed March 19, 2026. This was a sale (not a purchase) and appears to be a routine disposition to satisfy tax obligations.

Key Details

• Transaction date and price: 2026-03-17 — 4,302 shares sold at $99.48 each (total ~$427,965).
• Transaction type: Open-market sale reported under code S; executed pursuant to a pre-existing Rule 10b5-1 instruction.
• Shares owned after transaction: Beneficial ownership reported to include 84,250 RSUs (per footnote). The filing does not state a full post-transaction total beyond that inclusion.
• Footnotes: F1 — sale made under a 10b5-1 plan adopted 5/31/2023 to satisfy tax withholding on RSU vesting after 7/15/2023. F2 — indicates the position includes 84,250 RSUs.
• Filing timeliness: Form 4 filed 3/19/2026 for a 3/17/2026 transaction (filed within the typical reporting window).

Context
Sales executed under 10b5-1 plans are typically pre-planned to cover taxes or diversify and are often considered routine rather than an active signal of insider sentiment. For retail investors, purchases tend to carry more weight as potential bullish signals; this reported transaction reflects a tax-withholding related sale.